Chartered Trade Mark Attorney, Alexandra Nott explores some of the reasons that trade mark protection remains crucial in today’s business environment.
READ MORE
In this insight, Biotechnology partner Kit Wilkins reviews the US Supreme Court’s decision to Consider “Skinny Labels” in Generic Drug Patent Dispute. The decision could result in significant implications of generic medicines in the US.
READ MORE
In this insight, Holly Rocliffe from Dehns Biotechnology group explores the recently handed down decision in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd [2025] FCAFC 161[1], in which the Full Court of the Federal Court of Australia (Full Court) has ruled that patent term extension (PTE) is only available for patents which claim an active pharmaceutical ingredient (API).
READ MORE
The first decision from the UPC on sufficiency — handed down in the Amgen v. Sanofi case — provides the first clear guidance on how the court will address whether a patent’s disclosure is sufficient.
READ MORE
In this insight, Dehns Partner Rob Jackson and Conor Wilman from our Technology, Software and Engineering group explore the UPC’s Court of Appeal recent issues of two important decisions about how it will assess inventive step in patent cases.
READ MORE
The UPC: the 5 Ws (and an H): Mark Bell, Partner at Dehns provides a thorough breakdown of the UPC.
After many years of planning, numerous stop-starts and a huge amount of hard work, it’s finally here: the Unified Patents Court (UPC), a game-changer in European patent law, is now open for business.
Nikolle Medford, Trade Mark Assistant at Dehns discusses some high-profile trade mark disputes and how they played out in the public eye.
Plausibility after Warner-Lambert and G2/21: Paul Harris, Head of Litigation at Dehns, provides a case analysis of Sandoz and Teva v Bristol Myers Squibb – Court of Appeal.
Tesco Shown a Yellow (Club) Card: Daniel Wheatley, Trade Mark Assistant at Dehns provides a case analysis of Lidl Great Britain Ltd & Anor v Tesco Stores Ltd & Anor [2023] EWHC 873 (Ch).
Future royalty term considerations at early stage R&D licences: In this article, David Pountney, Senior Associate, Litigation at Dehns provides a case analysis of AstraZeneca UK Ltd v Tesaro Inc.
Join us in celebrating the work of trailblazing women around the world and in raising awareness about why it is so important to encourage more women to participate in the IP system, to protect their valuable IP and commercialise their ideas.
To celebrate our own “Women in IP” we’re taking this opportunity to introduce Hanna Dzieglewska – Head of Dehns Biotechnology team.
Join us in celebrating the work of trailblazing women around the world and in raising awareness about why it is so important to encourage more women to participate in the IP system, to protect their valuable IP and commercialise their ideas.
To celebrate our own “Women in IP” we’re taking this opportunity to introduce Elaine Deyes – Head of Dehns Trade Mark Group.
The theme for World Intellectual Property Day 2023 is Women and IP: Accelerating Innovation and Creativity. To highlight the innovative women in our network, we interviewed some of our contacts who are working on innovative solutions that challenge the status quo.
The theme for World Intellectual Property Day 2023 is Women and IP: Accelerating Innovation and Creativity. To highlight the innovative women in our network, we interviewed a few of our contacts who are working on innovative solutions that challenge the status quo.
Subscribe here for updates on IP news, events and webinars.
|